Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Frank Buck who wrote (1219)	1/20/1998 2:46:00 PM
From: george	Read Replies (1) \| Respond to of 1894

Frank I thought Sakura was to put 6m into New Co. George

To: Frank Buck who wrote (1219)	1/21/1998 1:46:00 AM
From: Cisco	Read Replies (2) \| Respond to of 1894

Frank, Since it is late, only a couple of comments tonight. I just finished listening to the call a little earlier. I had one of my staff tape the call so I could listen to it while I was driving home. You reported that: ®The newly developed lung cancer detection device (using cytometric evaluation) will be able to detect 90% of screened lung cancer at a Stage 0 or Stage 1 phase. Presently only 10% is detected at Stage 3 phase.¯ I believe those were survival rates not detection rates. Here is a direct quote from Peter Gombrich: ®Consider the benefits to (a) lung cancer patient, where disease today can only be detected today by X-ray at stage 3 with a 10% survival rate. Early studies have shown that (with) our technology, the disease can be detected at stage 0 or 1 resulting in a 90 % survival rate.¯ Here is another quote from Len to add to what you have posted: ®We believe that 6 million dollars will be more than sufficient to fund the operation of the business (NewCo) to the point at which we start generating positive cash out of sells and profitability.¯ Mr. Gombrich also stated that Boston was only the first of several planned seminars on the role of AccuMed in the Cytology Laboratory of the Future. Cites to follow beginning Feb. 11, 1998 and continuing over the next few months include San Francisco, New York, London, Chicago, Los Angeles, Atlanta, and Tokyo. Frank, I didn't know that AccuMed had a patented invivo specimem collection system. What is it? Another interesting piece of information was that Sakura controlled over 60% of the market on some cytopathological supplies. This should open a lot of doors for AccuMed! I believe you got all the other highlights I noticed! Basically, I liked what I heard. The future looks bright for the company. From what I heard, I would certainly start looking for profitability for AccuMed by end of 2nd quarter. Cisco